Amrn buyout- Will probably or almost definitely not happen without reduce it results. Can never expect a buyout and to be honest the price jump with those results and no buyout will be enough for all investors.
My experience on Vascepa is somewhat limited as I have to be honest. Colleagues in a Family practice office used to prescribe it well before I told them about it. I currently work in an ER so I don't prescribe it because that's not my scope of practice. I do see people come in with it on their med list from time to time and I ask them about it and no one has ever mentioned any side effects from it (maybe 25 -30 patients ). That N is very small but just my limited personal experience as you asked.
Market Data 
Markets 
AI
